natgillin/translations-raw huggingface dataset:
(It is also better to avoid CoAprovel in early pregnancy - see pregnancy section) if you have severe liver or kidney problems if you have difficulty in producing urine if your doctor determines that you have persistently high calcium or low potassium levels in your blood if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.
Nemojte uzimati CoAprovel ako ste alergični na irbesartan ili neki drugi sastojak ovoga lijeka (naveden u dijelu 6.) ako ste alergični na hidroklorotiazid ili neki drugi lijek koji je derivat sulfonamida ako ste trudni više od 3 mjeseca (preporučuje se također izbjegavati CoAprovel i u ranoj trudnoći - vidjeti dio o trudnoći) ako imate teških problema s jetrom ili bubrezima ako imate poteškoća sa stvaranjem urina ako liječnik utvrdi da imate stalno povišenu razinu kalcija ili nisku razinu kalija u krvi ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren
CoAprovel 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
CoAprovel 150 mg/12,5 mg filmom obložene tablete dostupne su u blister pakiranjima od 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta.
Cartons of 14 tablets in PVC/PVDC/Aluminium blisters.
Kutija s 14 tableta u PVC/PVDC/aluminij blisterima.
NAME OF THE MEDICINAL PRODUCT CoAprovel 300 mg/25 mg tablets irbesartan/hydrochlorothiazide NAME OF THE MARKETING AUTHORISATION HOLDER sanofi-aventis groupe EXPIRY DATE
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NAZIV LIJEKA CoAprovel 300 mg/25 mg tablete irbesartan/hidroklorotiazid NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET sanofi-aventis groupe ROK VALJANOSTI
EU/1/98/086/007 - 14 tablets EU/1/98/086/001 - 28 tablets EU/1/98/086/002 - 56 tablets EU/1/98/086/009 - 56 x 1 tablets EU/1/98/086/003 - 98 tablets
EU/1/98/086/007 - 14 tableta EU/1/98/086/001 - 28 tableta EU/1/98/086/002 - 56 tableta EU/1/98/086/009 - 56 x 1 tableta EU/1/98/086/003 - 98 tableta
However, another angiotensin-II antagonist affected fertility parameters in animal studies when given alone.
Rezultati istraživanja na životinjskim modelima pokazali su, međutim, da je jedan drugi antagonist receptora angiotenzina II primijenjen sam utjecao na parametre plodnosti.
Each tablet of CoAprovel 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Jedna CoAprovel 300 mg/12,5 mg tableta sadrži 300 mg irbesartana i 12,5 mg hidroklorotiazida.
Cartons of 56 tablets in PVC/PVDC/Aluminium blisters.
Kutija s 56 tableta u PVC/PVDC/aluminij blisterima.
CoAprovel 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
CoAprovel 150 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Cartons of 98 tablets in PVC/PVDC/Aluminium blisters.
Kutija s 98 tableta u PVC/PVDC/aluminij blisterima.
Sanofi Bulgaria EOOD Тел.
Sanofi Malta Ltd.
Package leaflet: Information for the patient CoAprovel 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Uputa o lijeku: Informacija za bolesnika CoAprovel 300 mg/25 mg filmom obložene tablete irbesartan/hidroklorotiazid
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 150 mg irbesartana i 12,5 mg hidroklorotiazida.
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
CoAprovel 300 mg/25 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2788 na drugoj strani.
NAME OF THE MEDICINAL PRODUCT CoAprovel 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide NAME OF THE MARKETING AUTHORISATION HOLDER sanofi-aventis groupe EXPIRY DATE
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NAZIV LIJEKA CoAprovel 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET sanofi-aventis groupe ROK VALJANOSTI
CoAprovel 300 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets.
CoAprovel 300 mg/12,5 mg filmom obložene tablete dostupne su u blister pakiranjima od 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta.
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00
T/A SANOFI Tel: +353 (0) 1 403 56 00
dizziness
Doziranje
Cartons of 28 tablets in PVC/PVDC/Aluminium blisters.
Kutija s 28 tableta u PVC/PVDC/aluminij blisterima.
Cartons of 30 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 30 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
Polska sanofi-aventis Sp. z o.o.
Polska sanofi-aventis Sp. z o.o. Tel.: +48 22 280 00 00
CoAprovel 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
CoAprovel 150 mg/12,5 mg filmom obložene tablete irbesartan/hidroklorotiazid
What CoAprovel looks like and contents of the pack CoAprovel 150 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
CoAprovel 150 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2875 na drugoj strani.
Each film-coated tablet of CoAprovel 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide.
Jedna CoAprovel 150 mg/12,5 mg filmom obložena tableta sadrži 150 mg irbesartana i 12,5 mg hidroklorotiazida.
EU/1/98/086/023 - 14 tablets EU/1/98/086/024 - 28 tablets EU/1/98/086/031 - 30 tablets EU/1/98/086/025 - 56 tablets EU/1/98/086/028 - 56 x 1 tablets EU/1/98/086/026 - 84 tablets EU/1/98/086/034 - 90 tablets EU/1/98/086/027 - 98 tablets
EU/1/98/086/023 - 14 tableta EU/1/98/086/024 - 28 tableta EU/1/98/086/031 - 30 tableta EU/1/98/086/025 - 56 tableta EU/1/98/086/028 - 56 x 1 tableta EU/1/98/086/026 - 84 tableta EU/1/98/086/034 - 90 tableta EU/1/98/086/027 - 98 tableta
cough
kašalj
Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
Bikonveksna, ovalna tableta boje breskve s utisnutom oznakom srca na jednoj i brojem 2776 na drugoj strani.
diarrhoea
Dojenje
EU/1/98/086/011 - 14 tablets EU/1/98/086/012 - 28 tablets EU/1/98/086/029 - 30 tablets EU/1/98/086/013 - 56 tablets EU/1/98/086/014 - 56 x 1 tablets EU/1/98/086/021 - 84 tablets EU/1/98/086/032 - 90 tablets EU/1/98/086/015 - 98 tablets
EU/1/98/086/011 - 14 tableta EU/1/98/086/012 - 28 tableta EU/1/98/086/029 - 30 tableta EU/1/98/086/013 - 56 tableta EU/1/98/086/014 - 56 x 1 tableta EU/1/98/086/021 - 84 tableta EU/1/98/086/032 - 90 tableta EU/1/98/086/015 - 98 tableta
Cartons of 56 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 56 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
Cartons of 90 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 90 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
Bikonveksna, ovalna tableta boje breskve s utisnutom oznakom srca na jednoj i brojem 2876 na drugoj strani.
Thu
U
EU/1/98/086/016 - 14 tablets EU/1/98/086/017 - 28 tablets EU/1/98/086/030 - 30 tablets EU/1/98/086/018 - 56 tablets EU/1/98/086/019 - 56 x 1 tablets EU/1/98/086/022 - 84 tablets EU/1/98/086/033 - 90 tablets EU/1/98/086/020 - 98 tablets
EU/1/98/086/016 - 14 tableta EU/1/98/086/017 - 28 tableta EU/1/98/086/030 - 30 tableta EU/1/98/086/018 - 56 tableta EU/1/98/086/019 - 56 x 1 tableta EU/1/98/086/022 - 84 tableta EU/1/98/086/033 - 90 tableta EU/1/98/086/020 - 98 tableta
Each film-coated tablet of CoAprovel 300 mg/12.5 mg contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide.
Jedna CoAprovel 300 mg/12,5 mg filmom obložena tableta sadrži 300 mg irbesartana i 12,5 mg hidroklorotiazida.
Cartons of 84 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 84 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
CoAprovel 300 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2876 na drugoj strani.
Cartons of 14 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 14 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 300 mg irbesartana i 12,5 mg hidroklorotiazida.
CoAprovel 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
CoAprovel 300 mg/12,5 mg filmom obložene tablete irbesartan/hidroklorotiazid
Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
Bikonveksna, ovalna tableta boje breskve s utisnutom oznakom srca na jednoj i brojem 2775 na drugoj strani.
Pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
Bikonveksna, ovalna tableta boje breskve s utisnutom oznakom srca na jednoj i brojem 2788 na drugoj strani.
CoAprovel 150 mg/12.5 mg film-coated tablets.
NAZIV LIJEKA CoAprovel 150 mg/12,5 mg filmom obložene tablete
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 300 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna tableta sadrži 300 mg irbesartana i 12,5 mg hidroklorotiazida.
Lactose monohydrate Microcrystalline cellulose Croscarmellose sodium Pregelatinised starch Silicon dioxide Magnesium stearate Red and yellow ferric oxides
Jezgra tablete: laktoza hidrat celuloza, mikrokristalična karmelozanatrij, umrežena škrob, prethodno geliran silicijev dioksid magnezijev stearat željezov oksid, crveni i žuti
Cartons of 28 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 28 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
What CoAprovel looks like and contents of the pack CoAprovel 150 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
CoAprovel 150 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2775 na drugoj strani.
Package leaflet: Information for the patient CoAprovel 150 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Uputa o lijeku: Informacija za bolesnika CoAprovel 150 mg/12,5 mg filmom obložene tablete irbesartan/hidroklorotiazid
Peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
Bikonveksna, ovalna tableta boje breskve s utisnutom oznakom srca na jednoj i brojem 2875 na drugoj strani.
Package leaflet: Information for the patient CoAprovel 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Uputa o lijeku: Informacija za bolesnika CoAprovel 150 mg/12,5 mg tablete irbesartan/hidroklorotiazid
What CoAprovel looks like and contents of the pack CoAprovel 300 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
CoAprovel 300 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2776 na drugoj strani.
Package leaflet: Information for the patient CoAprovel 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
Uputa o lijeku: Informacija za bolesnika CoAprovel 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide.
Jedna tableta sadrži 150 mg irbesartana i 12,5 mg hidroklorotiazida
Cartons of 98 film-coated tablets in PVC/PVDC/Aluminium blisters.
Kutija s 98 filmom obloženih tableta u PVC/PVDC/aluminij blisterima.
Package leaflet: Information for the patient CoAprovel 300 mg/12.5 mg film-coated tablets irbesartan/hydrochlorothiazide
Uputa o lijeku: Informacija za bolesnika CoAprovel 300 mg/12,5 mg filmom obložene tablete irbesartan/hidroklorotiazid
Excipient with known effect: Each film-coated tablet contains 38.5 mg of lactose (as lactose monohydrate).
Jedna filmom obložena tableta sadrži 38,5 mg laktoze (u obliku laktoze hidrata).
Slovenija sanofi-aventis d.o.o.
France sanofi-aventis France
Each tablet contains: irbesartan 300 mg and hydrochlorothiazide 12.5 mg
Jedna tableta sadrži 300 mg irbesartana i 12,5 mg hidroklorotiazida
Hypromellose Titanium dioxide Macrogol 3350
Film ovojnica: laktoza hidrat hipromeloza titanijev dioksid makrogol 3350 željezov oksid, crveni i crni karnauba vosak
Microcrystalline cellulose Croscarmellose sodium Lactose monohydrate Magnesium stearate Colloidal hydrated silica Pregelatinised maize starch Red and yellow ferric oxides (E172)
6.1 Popis pomoćnih tvari celuloza, mikrokristalična karmelozanatrij, umrežena laktoza hidrat magnezijev stearat silicijev dioksid, koloidni, hidratizirani kukuruzni škrob, prethodno geliran željezov oksid, crveni i žuti (E172)
Treatment is given for 5 to 14 days.
Terapija se daje od 5 do 14 dana.
Quofenix must not be used in children or adolescents under 18 years of age.
Quofenix se ne smije primjenjivati u djece ili adolescenata mlađih od 18 godina.
Further information on Quofenix can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/quofenix.
Više informacija o lijeku Quofenix dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/quofenix.
As a result, the bacteria cannot multiply and die.
Kao rezultat toga, bakterije se ne mogu umnožavati i odumiru.
After starting with a drip, the doctor may decide to switch to a tablet by mouth once every 12 hours.
Nakon početne terapije ukapavanjem liječnik može odlučiti prijeći na peroralnu primjenu tableta svakih 12 sati.
Quofenix (delafloxacin) EMA/572803/2019
Quofenix (delafloksacin) EMA/572803/2019
The main measure of effectiveness in both studies was whether the infection was cured.
Glavno mjerilo učinkovitosti u obama ispitivanjima bila je uspješnost izlječenja infekcije.
Quofenix is given by infusion (drip) into a vein over one hour every 12 hours.
Quofenix se primjenjuje intravenskom infuzijom (ukapavanjem) u trajanju od jednoga sata svakih 12 sati.
Quofenix (delafloxacin)
Quofenix (delafloksacin)
Quofenix is available as a powder to be made into a solution for infusion (300 mg) and as tablets (450 mg).
Quofenix je dostupan kao prašak od kojeg se priprema otopina za infuziju (300 mg) i kao tablete (450 mg).
It must not be used in women who are pregnant or breast feeding, or women who are able to have children who are not using contraception.
Ne smije se primjenjivati u žena koje su trudne ili koje doje ili žena u reproduktivnoj dobi koje ne koriste kontracepciju.
What measures are being taken to ensure the safe and effective use of Quofenix?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Quofenix?
Since Quofenix's safety profile was similar to that of other fluoroquinolones, it was considered that, as for other fluoroquinolones, it should be authorised for use only when other antibiotics are not suitable.
Budući da je sigurnosni profil lijeka Quofenix sličan onom kod drugih fluorokinolona, smatra se da kao i kod drugih fluorokinolona lijek treba biti odobren za primjenu samo kada drugi antibiotici nisu prikladni.
Quofenix has a different chemical structure to other fluoroquinolones, which means that it can enter bacterial cells more easily.
Quofenix ima drukčiju kemijsku strukturu od ostalih fluorokinolona, što znači da lakše ulazi u stanice bakterije.
Side effects reported with Quofenix are carefully evaluated and any necessary action taken to protect patients.
Nuspojave prijavljene za lijek Quofenix pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
The European Medicines Agency decided that Quofenix's benefits are greater than its risks and it can be authorised for use in the EU.
Europska agencija za lijekove zaključila je da koristi od lijeka Quofenix nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Quofenix have been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Quofenix nalaze se u sažetku opisa svojstava i u uputi o lijeku.
Fluoroquinolones work by preventing bacteria involved in skin infections from making copies of their DNA (genetic material).
Fluorokinoloni djeluju tako što sprječavaju bakterije koje uzrokuju infekciju da stvaraju kopije svojeg DNK-a (genetskog materijala).
Quofenix can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.
Quofenix se izdaje samo na recept, a liječnici koji propisuju lijek trebaju uzeti u obzir službene smjernice o primjerenoj upotrebi antibiotika.
The active substance in Quofenix, delafloxacin, belongs to a group of antibiotics called fluoroquinolones.
Djelatna tvar u lijeku Quofenix, delafloksacin, pripada skupini antibiotika naziva fluorokinoloni.
What is Quofenix and what is it used for?
Što je Quofenix i za što se koristi?
Other information about Quofenix
Ostale informacije o lijeku Quofenix
As for all medicines, data on the use of Quofenix are continuously monitored.
Kao i za sve lijekove, podatci o primjeni lijeka Quofenix kontinuirano se prate.
For more information about using Quofenix, see the package leaflet or contact your doctor or pharmacist.
Za više informacija o primjeni lijeka Quofenix pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
Quofenix was shown to be as effective as alternative antibiotics in two main studies of adults with acute bacterial skin and skin structure infections.
Lijek Quofenix pokazao se jednako učinkovitim kao alternativni antibiotici u dvama glavnim ispitivanjima u odraslih bolesnika s akutnim bakterijskim infekcijama kože i kožnih struktura.
Quofenix must not be used in patients who are hypersensitive (allergic) to quinolone or fluoroquinolone antibiotics or in patients who have had tendon disorders related to treatment with a fluoroquinolone antibiotic.
Quofenix se ne smije primjenjivati u bolesnika koji su preosjetljivi (alergični) na antibiotike kinolone ili fluorokinolone ili u bolesnika koji su imali poremećaje tetiva povezane s primjenom antibiotika fluorokinolona.
Quofenix is an antibiotic used in adults to treat bacterial infections of the skin and underlying tissues (acute bacterial skin and skin structure infections) when other medicines are not suitable.
Quofenix je antiobiotik koji se u odraslih osoba koristi za liječenje bakterijskih infekcija kože i potkožnih tkiva (akutnih bakterijskih infekcija kože i kožnih struktura) kad se upotreba drugih lijekova smatra neprikladnom.
Why is Quofenix authorised in the EU?
Zašto je lijek Quofenix odobren u EU-u?
An overview of Quofenix and why it is authorised in the EU
Pregled informacija o lijeku Quofenix i zašto je odobren u EU-u
The most common side effects with Quofenix (which may affect up to 1 in 10 people) are diarrhoea and nausea (feeling sick), which are mild to moderate.
Najčešće nuspojave lijeka Quofenix (koje se mogu javiti u do 1 na 10 osoba) jesu proljev i mučnina te su blage do umjerene.
It contains the active substance delafloxacin.
Sadrži djelatnu tvar delafloksacin.
What are the risks associated with Quofenix?
Koji su rizici povezani s lijekom Quofenix?
After treatment for up to 14 days, 58% of patients who received Quofenix were cured of their infection compared with 60% of patients who received vancomycin and aztreonam.
Nakon najviše 14 dana terapije 58 % bolesnika koji su primali lijek Quofenix bili su izliječeni od infekcije u usporedbi sa 60 % bolesnika koji su primali vankomicin i aztreonam.
Quofenix is as effective as alternative antibiotics given into a vein in treating acute bacterial skin and skin structure infections and offers the possibility of switching to treatment by mouth, which may be more convenient for the patient and could reduce hospitalisation costs.
Lijek Quofenix jednako je učinkovit kod liječenja akutnih bakterijskih infekcija kože i kožnih struktura kao i alternativni antibiotici koji se daju u obliku infuzije te za njega postoji mogućnost prelaska na peroralnu primjenu, što može biti praktičnije za bolesnika i može smanjiti troškove hospitalizacije.
How does Quofenix work?
Kako djeluje Quofenix?
In the first study involving 660 patients, Quofenix given into a vein was compared with vancomycin plus aztreonam (two other antibiotics) both given into a vein.
U prvom ispitivanju koje je obuhvaćalo 660 bolesnika lijek Quofenix primijenjen u obliku infuzije uspoređivan je s vankomicinom i aztreonamom (druga dva antibiotika) primijenjenima u obliku
In the second study involving 850 patients, Quofenix given into a vein for 3 days and afterwards given as tablets by mouth was compared with vancomycin plus aztreonam given into a vein.
U drugom ispitivanju koje je obuhvaćalo 850 bolesnika lijek Quofenix, koji je primjenjivan prva tri dana u obliku infuzije i nakon toga peroralno u obliku tableta, uspoređivan je s vankomicinom i aztreonamom koji su primjenjivani u obliku infuzije.
For the full list of side effects and restrictions with Quofenix, see the package leaflet.
Potpuni popis nuspojava i ograničenja povezanih s primjenom lijeka Quofenix potražite u uputi o lijeku.
What benefits of Quofenix have been shown in studies?
Koje su koristi od lijeka Quofenix utvrđene u ispitivanjima?
Persistent and disabling side effects have occurred with fluoroquinolone antibiotics in some patients.
Neki od bolesnika koji su uzimali antibiotike fluorokinolone imali su trajne i onesposobljavajuće nuspojave.
patients treated with Quofenix were cured of their infection, compared with 51% of patients treated with vancomycin and aztreonam.
Nakon najviše 14 dana terapije 52 % bolesnika koji su primali lijek Quofenix izliječeni su od infekcije u usporedbi s 51 % bolesnika koji su liječeni vankomicinom i aztreonamom.
This overview was last updated in September 2019.
Ovaj pregled informacija posljednji je put ažuriran u rujnu 2019.
Virulent means that the virus is capable of producing severe disease.
Virulentan znači da virus može prouzročiti tešku bolest.
Further information on Gumbohatch can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/gumbohatch.
Više informacija o cjepivu Gumbohatch dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/veterinary/EPAR/gumbohatch.
Studies have shown the start of protection to be from between 24 days of age and 28 days of age.
Ispitivanja su pokazala da zaštita počinje u razdoblju između 24. i 28. dana starosti.
Gumbohatch was investigated in 5 laboratory and 3 field studies.
Cjepivo Gumbohatch ispitivano je u pet laboratorijskih i tri terenska ispitivanja.
Protection against IBD starts from between 24 to 28 days of age and lasts up to 43 days of age.
Zaštita od zarazne bolesti burze započinje između 24. i 28. dana starosti i traje do 43. dana starosti.
This loss of lymphocytes does not cause immunosuppression in the chickens.
Gubitak limfocita ne uzrokuje imunosupresiju kod pilića.
The start of protection depends on the initial maternal antibody level of the batch of chickens and even then will be different for individual chickens.
Početak zaštite ovisi o početnoj razini majčinskih protutijela u određenoj seriji pilića, a čak i tada će biti odstupanja među pojedinim pilićima.
What is the withdrawal period in food-producing animals?
Koje je razdoblje karencije u životinja koje se koriste za proizvodnju hrane?